» Authors » Nawal M Alrasheed

Nawal M Alrasheed

Explore the profile of Nawal M Alrasheed including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 16
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Alobaid S, Alshahrani R, Alonazi A, Alrasheed N, Alamin M, Alshammari T, et al.
Pharmaceuticals (Basel) . 2024 Mar; 17(3). PMID: 38543160
One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase...
2.
Bin Dayel A, Alonazi A, Alrasheed N, Alamin M, Sarawi W, Alharbi A, et al.
J Pharm Pharmacol . 2023 Nov; 76(1):64-73. PMID: 37992247
Objectives: Diabetic cardiomyopathy is a known complication of diabetes mellitus. Herein, we aimed to determine whether glycemic control mediated by sitagliptin, a dipeptidyl peptidase-4 inhibitor, can ameliorate diabetic myocardial abnormalities...
3.
Al-Qabbaa S, Qaboli S, Alshammari T, Alamin M, Alrajeh H, Almuthnabi L, et al.
Int J Mol Sci . 2023 Apr; 24(7). PMID: 37047505
Diabetic nephropathy (DN) is a microvascular complication of diabetes mellitus. This study examined the therapeutic effects of sitagliptin, a dipeptidyl peptidase inhibitor, on DN and explored the underlying mechanism. Male...
4.
Alrasheed N, Alammari R, Alshammari T, Alamin M, Alharbi A, Alonazi A, et al.
BMC Cardiovasc Disord . 2023 Mar; 23(1):153. PMID: 36964489
Background: Myocardial infarction (MI) is considered a public health problem. According to the World Health Organization, MI is a leading cause of death and comorbidities worldwide. Activation of the α1A...